Medicines and Healthcare products Regulatory Agency

Medicines and Healthcare products Regulatory Agency (MHRA) is a UK government agency responsible for ensuring that medicines and medical devices meet applicable standards of safety, quality, and efficacy. The MHRA is part of the Department of Health and Social Care and oversees the regulation of medicines, medical devices, and blood components for transfusion in the UK.

History

The MHRA was formed in 2003 through the merger of the Medicines Control Agency (MCA) and the Medical Devices Agency (MDA). The merger aimed to streamline and improve the regulation of medicines and medical devices within the UK.

Functions

The primary functions of the MHRA include:

• Assessing and authorizing pharmaceutical drugs for use in the UK.
• Overseeing the safety of medicines, medical devices, and blood components through post-market surveillance and adverse event reporting.
• Regulating clinical trials of new medicines and devices.
• Enforcing standards and regulations to ensure the safety and efficacy of medical products.
• Providing information to healthcare professionals and the public about the risks and benefits of medical products.

Regulatory Framework

The MHRA operates under a regulatory framework that includes several key pieces of legislation, such as the Medicines Act 1968, the Medical Devices Regulations 2002, and regulations stemming from the European Union, although post-Brexit, the UK's regulatory landscape is subject to change.

Brexit and the MHRA

Following the UK's departure from the European Union, the MHRA has taken on additional responsibilities that were previously managed at the EU level by the European Medicines Agency (EMA). This transition requires the MHRA to adapt its regulatory processes to ensure that patients in the UK continue to have timely access to safe and effective medical products.

Public Health Responsibilities

In addition to its regulatory functions, the MHRA plays a critical role in public health. This includes responding to health emergencies, managing drug shortages, and contributing to global health initiatives.

Criticism and Challenges

The MHRA has faced criticism over its handling of certain medical products and its perceived closeness to the pharmaceutical industry. Ensuring transparency, independence, and public trust remains an ongoing challenge for the agency.

See Also

• Pharmaceutical industry in the United Kingdom
• Clinical trial
• European Medicines Agency
• Food and Drug Administration (FDA) - The United States' equivalent regulatory agency.

‎ ‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian